Balanced news tone
News Sentiment
LEXX sentiment intelligence
Lexaria Bioscience Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
52 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+15.4% over one week, +5.2% over four weeks, trend inactive, and below fair value.
Lexaria Bioscience narrows Q3 loss to $(0.08) per share
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
15.4%
Price confirming higher
Trend fit
Trend inactive
5.2% over four weeks
Fair value
-60.3%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
32
Negative
6
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
ACCESS Newswire
Direct company coverage
Lexaria Updates Progress on Human Study #7
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 13:10
- Source
- ACCESS Newswire
Stock Titan
Direct company coverage
Lexaria targets mid-June start for 5-week oral semaglutide study
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Stock Titan
ACCESS Newswire
Direct company coverage
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 May 2026 13:25
- Source
- ACCESS Newswire
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Can Lexaria Bioscience (NASDAQ:LEXX) Afford To Invest In Growth?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Apr 2026 07:00
- Source
- simplywall.st
Market source
Direct company coverage
Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 15 Apr 2026 07:00
- Source
- Market source
Quiver Quantitative
Direct company coverage
LEXARIA BIOSCIENCE ($LEXX) Releases Q2 2026 Earnings | LEXX Stock News
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Apr 2026 07:00
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
A third oral GLP-1 wins FDA approval, and Lexaria sees an opening
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 07 Apr 2026 07:00
- Source
- Stock Titan
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Investing News Network
Direct company coverage
Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Sep 2025 07:00
- Source
- Investing News Network
GuruFocus
Direct company coverage
Lexaria Bioscience (LEXX) Expands Global Patent Portfolio with N
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 23 Jun 2025 07:00
- Source
- GuruFocus
Investing News Network
Direct company coverage
Lexaria Bioscience
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Apr 2023 11:47
- Source
- Investing News Network
TMX Newsfile
Direct company coverage
Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jan 2021 08:00
- Source
- TMX Newsfile
MarketBeat
Direct company coverage
Lexaria Bioscience (LEXX) Stock Price, News & Analysis $LEXX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jan 2021 01:03
- Source
- MarketBeat
Zacks Investment Research
Direct company coverage
Lexaria Bioscience (LEXX)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jan 2021 12:04
- Source
- Zacks Investment Research
TradingView
Direct company coverage
LEXX Stock Price and Chart — NASDAQ:LEXX
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jan 2021 19:16
- Source
- TradingView
Investing News Network
Direct company coverage
Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jan 2021 08:00
- Source
- Investing News Network
TMX Newsfile
Direct company coverage
Lexaria Welcomes New Medical Marijuana Expert Advisor
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Mar 2014 07:00
- Source
- TMX Newsfile